Hebei Tianao Technology Co.,Ltd

Tranexamic acid is a derivative of aminotoluic acid, is an anti-fibrinolytic hemostatic drug, the hemostatic mechanism is the same as aminocaproic acid, aminotoluic acid, but the effect is stronger, the strength is 7~10 times that of aminocaproic acid, 2 times that of aminotoluic acid, and the toxicity is similar. The chemical structure of tranexamic acid is similar to that of lysine, which can competitively inhibit the adsorption of plasminogen on fibrin, prevent its activation, protect fibrin from being degraded and dissolved by plasmin, and finally achieve hemostasis. It is suitable for the treatment of various bleeding caused by acute or chronic, localized or systemic primary fibrinolysis, such as obstetric hemorrhage, renal hemorrhage, prostatic hypertrophy hemorrhage, hemophilia, tuberculosis blood, gastric blood, liver, lung, spleen and other visceral bleeding after surgery, etc.; It can also be used for abnormal bleeding during surgery. Clinically, tranexamic acid has significant effects on insect bites, eczema dermatitis, simple purpura, chronic urticaria, artificial urticaria, toxic rash and drug eruption, and also has certain curative effects on erythroderma, scleroderma, SLE, erythema multiforme, herpes zoster and alopecia areata, and has a good effect on hereditary angioedema. The treatment of melasma is generally effective in about 3 weeks, 5 weeks, and a course of 60 days. 0.25~0.5g each time, 3~4 times a day. A small number of patients may experience side effects such as nausea, fatigue, itching, abdominal discomfort, and diarrhea, which disappear when the drug is stopped.